New molecular entity: Degarelix, a GnRH receptor antagonist, was approved on December 24, 2008, for the treatment of advanced prostate cancer
Degarelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds reversibly to the pituitary GnRH receptors; this action decreases the release of gonadotropins and testosterone. This agent was approved on December 24, 2008, for the treatment of patients with advanced prostate cancer.
Efficacy. The efficacy of degarelix was assessed in an open-label, multicenter, randomized, parallel-group study. Patients (N=620) were randomized to receive subcutaneous (SC) degarelix at a starting dose of 240 mg (40 mg/mL) followed by monthly doses of 160 mg (40 mg/mL), SC degarelix at a starting dose of 240 mg (40 mg/mL) followed by monthly doses of 80 mg (20 mg/mL), or intramuscular (IM) leuprolide 7.5 mg monthly for 1 year. Serum testosterone levels were measured at screening, on Days 0, 1, 3, 7, 14, and 28 in the first month, and monthly until study end. The median testosterone level at baseline was approximately 400 ng/dL. The primary goal was to evaluate the efficacy of degarelix in achieving and maintaining testosterone suppression to castration levels (≤50 ng/dL) over 1 year. Among patients treated with degarelix, 98.3% (95% CI, 94.8%–99.4%) of patients in the 240/160-mg dose group and 97.2% (95% CI, 93.5%–98.8%) of patients in the 240/80-mg dose group achieved this end point compared with 96.4% (95% CI, 92.5%–98.2%) of patients treated with leuprolide. Testosterone suppression to castration levels occurred more rapidly among degarelix patients, with 96% of degarelix-treated patients achieving this end point by Day 3 compared with 0 leuprolide-treated patients. Prostate-specific antigen (PSA) levels were assessed as a secondary end point. Among patients treated with degarelix, PSA levels were reduced by 64% at 2 weeks after treatment, by 85% after 1 month of treatment, and by 95% after 3 months of treatment; PSA levels remained suppressed throughout the year of treatment.
Safety. Degarelix should not be administered to women who are or who may become pregnant. Long-term androgen therapy has been demonstrated to prolong the QT interval. Healthcare professionals should weigh the benefits of treatment against the potential risks in patients with congenital long QT syndrome, electrolyte abnormalities, or congestive heart failure and in those taking class IA or III antiarrhythmic medications. Degarelix therapy suppresses the pituitary gonadal system; as such, diagnostic tests of the pituitary gonadotropic and gonadal functions may be affected during and after treatment. The most common adverse events associated with degarelix treatment include injection-site reactions (eg, pain, erythema, swelling, induration), hot flashes, increased weight, fatigue, and increases in serum levels of transaminases and gamma-glutamyltransferase (GGT).
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More